<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Soumya Sjg on Medium]]></title>
        <description><![CDATA[Stories by Soumya Sjg on Medium]]></description>
        <link>https://medium.com/@soumya.sjg?source=rss-7d63f288388a------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*ZUALyutqeyJPfioE</url>
            <title>Stories by Soumya Sjg on Medium</title>
            <link>https://medium.com/@soumya.sjg?source=rss-7d63f288388a------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 17:57:44 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@soumya.sjg/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Why does CAR-T therapy work so well for some blood cancers but struggle to eliminate solid tumours?]]></title>
            <link>https://medium.com/@soumya.sjg/why-does-car-t-therapy-work-so-well-for-some-blood-cancers-but-struggle-to-eliminate-solid-tumours-56b37e898447?source=rss-7d63f288388a------2</link>
            <guid isPermaLink="false">https://medium.com/p/56b37e898447</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[immunology]]></category>
            <category><![CDATA[cancer-treatments]]></category>
            <dc:creator><![CDATA[Soumya Sjg]]></dc:creator>
            <pubDate>Fri, 30 Oct 2026 18:27:42 GMT</pubDate>
            <atom:updated>2026-10-30T18:27:42.647Z</atom:updated>
            <content:encoded><![CDATA[<p>In 2012, six-year-old Emily Whitehead became <a href="https://www.chop.edu/news/emily-whitehead-first-pediatric-patient-receive-car-t-cell-therapy-celebrates-cure-10-years">the first paediatric patient to receive an experimental CAR-T cell therapy for leukaemia</a>. More than a decade later, she remains entirely cancer-free — a remarkable testament to CAR-T therapy’s life-changing potential.</p><p>If the immune system is built to protect us, why can cancer still escape it? Despite decades of advances in chemotherapy, immunotherapy and radiotherapy, cancer remains the second leading cause of death worldwide.</p><p>And here comes arguably one of the most transformative cancer-treating technologies to emerge, in 2012 — CAR-T therapy. It involves genetically modifying a patient’s T cells to recognise and attack cancer. And 10 years later? More than 34,000 patients worldwide had received commercially available CAR-T-cell therapies, while the ELIANA clinical trial reported remission in 81% of children and young adults with leukaemia that had returned or resisted treatment within three months of receiving this therapy.</p><p>Yet, despite these remarkable results, CAR-T therapy has not been equally successful across all cancers. While it has proved highly effective against certain blood cancers, it continues to struggle to eradicate solid tumours.</p><p>Emily’s story hasn’t just demonstrated how far cancer treatment has progressed. It has raised questions scientists are still trying to answer. If this treatment is so powerful, why doesn’t it work everywhere?</p><p><strong>What actually are CAR-T cells?</strong></p><p>Cancer does not appear overnight. It forms through irregularities in the nucleus’ DNA systems; abnormal genetic mutations that prevent cells from dying when damaged or old enough. In most cases, eventually developing a solid tumour which often invades healthy tissue. This is where T cells (CD8⁺ cytotoxic T cells) come in — white blood cells designed to carry out the immune’s system’s defensive response against abnormal, sometimes cancerous cells. Specifically, these cells mature in an organ called the thymus giving it its ‘T-cell’ name.</p><p>CAR-T is the decade-new therapy focused on genetically modifying these T cells, engineered to recognize a specific type of molecule (typically a protein).</p><p><strong>Chimeric</strong> — the improved cell is assembled from different components each with different biological functions.</p><p><strong>Antigen</strong> — A molecule or marker (often found on the surface of the cell) that the immune system can recognize and use to differentiate cancerous cells from healthy ones.</p><p><strong>Receptor</strong>: Part of the CAR-T cell, this protein helps actually recognize the antigen.</p><p><strong>How does CAR-T therapy actually work?</strong></p><p>Have you ever heard of the ‘living drug’? CAR-T cells are known by this nickname because unlike regular medical pills, they’re customised, upgraded in a laboratory and multiply inside you (whereas most infused pharmaceuticals naturally dissolve and disappear). They follow a four-step procedure (excluding the actual cancer-killing process):</p><p><strong>1)</strong> <strong>Collecting the T cells from the patient’s blood</strong> — This process is called leukapheresis, a procedure where white blood cells (including T-cells) are extracted through specialised blood filters. The cells are cryopreserved and any remaining blood components are returned to the patient.</p><p><strong>2)</strong> <strong>Genetically engineering the T cells</strong> — to ask first, why do we even modify regular immune cells? Normally, these T cells contain receptors informing them of particular targets (CD19, BCMA etc.) attached on the surface of cancerous cells however cancerous cells can evade this recognition, allowing them to ‘camouflage’ with healthy cells. Many misperceive how this genetic modification process actually works; a common misunderstanding is that scientists replace the modified receptor with the preexisting one however they actually edit the cell DNA for it to manufacture the engineered receptor itself.</p><p><strong>3)</strong> <strong>Multiplying the modified T cells in the laboratory — </strong>After genetic modification, engineered T-cells undergo a process called cell expansion under controlled laboratory conditions under the provision of nutrients and signals required for cell division to occur. Before release, these cells go through quality-control tests, not only measuring viability but purity and their ability to perform their intended function.</p><p><strong>4)</strong> <strong>Infusing the CAR-T cells back into the patient — </strong>Once manufactured CAR-T cells pass their required quality checks, they’re transported back to the treatment centre and infused intravenously through the patient’s bloodstream. Before the infusion, patients commonly undergo lymphodepleting chemotherapy, reducing number of existing immune cells for a short period to allow CAR-T cells to dominate, expand and function.</p><p><strong>What do CAR-T cells consist of?</strong></p><p><strong>Antigen recognition domain</strong> — a protein (specifically antibody) used to detect the chosen target on the cancer cell.</p><p><strong>Hinge and transmembrane domains</strong> — This connector and anchor helps position the receptor in the T-cell membrane, stabilizing it.</p><p><strong>Intracellular signalling domain</strong> — Transmit signals when the modified receptor (CAR) binds its target, supporting its ability to attack the cancerous cells.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*PqpoIpmtGZKuY95wwmN-YA.png" /><figcaption><strong>(CAR-T therapy process — Northside Hospital)</strong></figcaption></figure><p><strong>Why CAR-T therapy works so well in blood cancers:</strong></p><p>For an extended period, scientists studying CAR-T therapy have all been asking one question: why should the location of a cancer influence how effectively we can treat it?</p><p>If anything, when I first explored this topic, my assumption was that treatment would be easier in solid tumours since it excludes the unpredictable flow of blood and high likelihood of the cancer spreading elsewhere.</p><p>However, after research I realized that there were four features, in particular, that make blood cancers the ideal setting for this precision-engineered treatment.</p><p><strong>A clean target</strong> — When choosing what antigen the receptor should identify, scientists don’t look at abundancy (‘which protein appears on the surface of the most cancerous cells?’), instead prioritize observing the therapeutic window: the range in which treatment can attack enough cancer cells without causing irreversible harm. For example, this exists in most cases of B-cell cancers which include lymphomas, leukaemia or multiple myeloma. While this surface protein simultaneously exists on healthy cells, cell disruption and loss is manageable with patients able to receive immunoglobin replacement which supplies antibodies if cell count deteriorates.</p><p><strong>Easier physical access</strong> — Once CAR-T cells have been manufactured, they are infused into the bloodstream (intravenously). Many blood cancers (mostly liquid blood cancers like B-cell Acute Lymphoblastic Leukaemia, or B-ALL) arise in places which intervene in immune cells’ natural circulating system, encountering these abnormal cells as part of their normal movement throughout the bloodstream.</p><p><strong>A more tolerable environment</strong> — In many solid tumours, surrounding tissue create hostile, often hypoxic environments that actively suppress immune responses. Comparatively in haematological malignancies, cancer cells float in highly vascularized areas. They’re often provided with a constant stream of oxygen and essential nutrients (e.g. glucose and amino acids), therefore less likely to drain their energy from an insufferable, suffocating vicinity. In the wider scope, blood cancers are widely distributed, lacking a structural tissue wall, allowing CAR-T cells to identify and target cancer cells easily.</p><p><strong>Relatively uniform antigen</strong> — In blood cancers, homogeneity (similar antigens, less variety) allow the engineered receptor to identify a greater portion of the cancer cells, on what it was genetically modified to recognize and identify, leaving less unidentifiable cancer cells to survive.</p><p>Nearly a decade after the first CAR-T-cell therapies were approved in the US, the market for these treatments is predicted to grow at an annual compound growth rate of 17.0% between 2026 and 2033. Fundamentally, it showcases how this technology can help redefine boundaries of modern oncology. Yet, to arguably a greater extent, it also reflects upon the depths scientists need to reach to eliminate solid tumours…</p><p><strong>Why does CAR-T therapy struggle to eliminate solid tumours?</strong></p><p>Eliminating solid malignancies is far more complicated than it first appears — presenting an entirely new set of challenges that CAR-T therapy currently struggles to overcome. And the worst part? Solid tumours account for approximately 90% of all cancers…</p><p>A real case study from 2010 involving a patient diagnosed with metastatic colon cancer shows after HER2-directed CAR-T therapy developed severe respiratory distress and organ damage, dying five days later. Researchers attributed this event to severe immune reaction due to low levels of HER2 on healthy tissues, particularly in the lungs. It highlights the risks of targeting antigens not exclusive to cancer.</p><p>Recent reviews from <a href="https://pennmedicine.org/news/penn-medicine-at-the-aacr-annual-meeting-2026">Carl June (a Penn Pioneer widely renowned as ‘Father of CAR-T cell therapy’) at the AACR annual meeting</a>, and a growing consensus amongst biomedical journals namely Cell Reports Medicine, Nature, <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1045024/full">Frontiers in Immunology</a>, and the <a href="https://link.springer.com/doi/10.1186/s13045-025-01760-9">Journal of Haematology and Oncology</a>, show the five core barriers in solid tumours:</p><p><strong>No clean tumour specific target</strong> — Targeting specific surface proteins comes with one of the most detrimental impacts of CAR-T therapy: tumour-associated antigens, present on some healthy cells too. The result can be on-target, off-tumour toxicity, posing further problems to scientists who have to establish where else specific proteins are found and of what abundance and vitality.</p><p><strong>Poor T cell trafficking</strong> — Unlike haematological malignancies, solid tumours wrap themselves in dense stroma, extracellular matrix and disordered leaky vasculature. CAR-T cells must identify the tumour, survive the circulation, exit the blood vessels, penetrate the thick walls of the tumour and survive the immunosuppressive tumour microenvironment while activating each biological function to support its attack against the cancer cells.</p><p><strong>Deactivation of T cells in tumour microenvironment</strong> — When CAR-T cells reach the tumour, there lay numerous problems within the hostile environments including low oxygen (hypoxia), nutrient depletion and abundance of immunosuppressive cells that deactivate the cell’s capabilities. While cancer cells may naturally adapt to these anatomical barriers, these results disrupt immune cell-activity significantly. Suppressive immune cells, including regulatory T cells, myeloid-derived suppressor cells and tumour-associated macrophages, alongside signals such as TGF-β, PD-L1 and adenosine, weaken T-cell activity and hinder their attack against cancer cells.</p><p><strong>Antigen heterogeneity</strong> — If you look at an imaging scan of a solid tumour, cells can appear homogeneous however interiorly, cells aren’t necessarily identical — containing different genes, behaviours and displaying different proteins on the surface. Take an example of glioblastoma multiforme (the most aggressive type of cancerous brain tumour) consisting of multiple different molecules and so a CAR-T treatment for EGFRvIII Protein doesn’t eradicate IL13Rα2 or HER2 Protein.</p><p><strong>T-cell exhaustion and persistent stimulation</strong> — Normally when a CAR recognizes its target antigen, it sends signals into the T cell, leading to activation and an instant immune response — however in tumour microenvironments where the antigen is frequently presented, repeated activation signals lead to constant stimulation. On a comparative scale, it leads to CAR-T dysfunction far more rapidly than in blood cancers.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iZysoMb4b3QBKmH9z_EPAQ.png" /><figcaption><strong>(diagram of CAR-T cells in solid tumours — Nature)</strong></figcaption></figure><p>It was only on <a href="https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma">June 22, 2026 when China’s National Medical Products Administration (NMPA) granted the world’s first ever approval of CAR-T therapy for solid tumours</a>, conducted by the biotech firm <a href="https://www.carsgen.com/en/news/20260622/">CARsgen Therapeutics</a>. And what was the endline goal? To determine whether satri-cel (CAR-T cells with receptors designed to recognize Claudin18.2 for typically advanced stomach cancer) could compare with a physician’s typical choice of chemotherapeutic treatment for patients with preexisting failed records when it came to other types of cancer-treating therapy.</p><p>The data showed an <a href="https://www.themednet.org/publications/claudin-18-isoform-2-specific-car-t-cell-therapy-satri-cel-versus-treatment-of-physicians-choice-for-previously-treated-advanced-gastric-or-gastro-oesophageal-junction-cancer-ct041-st-01-a-randomised-open-label-phase-2-trial">improved median progression-free survival (the time a patient lives without their cancer getting worse) of 3.25 months compared to just 1.77 months</a> for those using standard chemotherapy. Perhaps the statistic that truly puts this into proper perspective is how <a href="https://www.sciencealert.com/?p=163433">22% of infused patients had significant tumour shrinkage (a reduction of at least 30%) compared to a minimal 4%</a> of patients on standard treatments.</p><p>Yet, while the figures highlight how this intense treatment provides patients with disease control and meaningful prolongation of life, it still doesn’t guarantee that long-term cure that happens so dramatically with CAR-T therapies in blood cancers. And imagine taking this extensive, sometimes inundating treatment, all to realize that it was not as effective as you wished…</p><p><strong>Solutions for CAR-T therapy to eliminate solid tumours:</strong></p><p>In the 1980s, immunologists first described the core concepts of engineering T-cells, introducing the idea of lab-modified receptors. Just thirty years later, a specialised oncologist team at UPenn genetically engineered CD19 CAR-T cells for leukaemia. And by 2026, the scope has expanded dramatically to <a href="https://bioinformant.com/car-t-market-leaders/amp/">16 approvals worldwide</a> and the world’s first ever approved CAR-T therapy for solid tumours on June, 22.</p><p>You might perceive this as the evolution of this technology — but the future of CAR-T therapy has just begun. And with that comes numerous companies, biotech firms, immunologists from worldwide destinations and a hundred more actively trying to decipher how CAR-T therapy can improve — and potentially eradicate solid tumours.</p><p><strong>Logic-gated CAR-T cells</strong> — The basic CAR-T design has a flaw: on-target, off-tumour toxicity. This engineered cell, instead of responding to a single antigen in isolation, combines information from multiple molecules on a cell’s surface, then proceeding on whether to attack or not.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*FGCPQg16WpwCnIj-QcGmvA.png" /><figcaption><strong>(Diagram of logic-gated CAR-T cells — ResearchGate)</strong></figcaption></figure><p><strong>Dual targeting</strong> — Imagine a solid tumour with a heterogeneous population — thousands of cancer cells displaying different antigens from one another. And then you have the issue of antigen-negative relapses (a random genetic mutation which make cancer cells, often permanently, lose their distinguishable antigen) which prevent a few cancer cells from being eradicated. This treatment aims to widen the range of antigens the CAR-T cells can target by engineering it to recognize two antigens — attacking cells with either or both antigens.</p><p><strong>Armoured CAR-T cells</strong> — In most cases, CAR-T cells encounter inhibitory chemical signals from the mass tumour that disrupt immune cell activity. An armoured CAR-T cell carries additional engineered features focused on helping it function in hostile tumour vicinities e.g. editing genetic code to produce a decoy receptor that soaks up TGF-β, preventing the tumour’s suppressive signals from reaching the CAR-T cell.</p><p><strong>Regional and local delivery</strong> — Standard CAR-T treatments involve intravenous infusion of modified T-cells into the bloodstream — wasting energy where T-cells circulate through the bloodstream, exit blood vessels and penetrate through dense tumour tissue before attacking the cancer cells. This treatment aims to place CAR-T cells into or near the tumour, helping to stabilize their journey from their infused position to actually within the tumour.</p><p><strong>Major companies leading the change (future):</strong></p><p>A2 Biotherapeutics — this firm has already attempted <a href="https://clinicaltrials.gov/study/NCT06051695">to put logic-gated CAR-T cells into play</a>; the clinical-stage biotech firm created a therapy that targets a protein called Mesothelin (highly expressed on solid tumours however exists at low levels in the linings of the lungs and heart). Scientists tried to engineer the T-cell with two separate receptors to recognize mesothelin and HLA-A*02 (a cell-surface marker appearing in some healthy tissue cells). The CAR-T cell activates when it detects mesothelin, however in instances when the cell simultaneously expresses HLA-A*02 it sends an inhibitory signal preventing any attack on healthy cells.</p><p><strong>UPenn Medical School </strong>— <a href="https://www.pennmedicine.org/news/dual-target-car-t-cell-therapy-slows-growth-of-aggressive-brain-cancer">Researchers at UPenn engineered a bivalent CAR-T therapy targeting both EGFR and IL13Rα2</a> for patients diagnosed with glioblastoma (highly heterogeneous type of brain cancer). When presented at the ASCO annual meeting, statistics showed a rapid progression for patients, causing tumour shrinkage in 62% of patients.</p><p><strong>City of Hope </strong>— <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11031404/">Researchers at City of Hope (a leading cancer speciality hospital)</a> wanted to investigate whether CAR-T cells could be delivered differently from the conventional intravenous infusion method. Their study involved treating 65 patients diagnosed with high-grade gliomas (aggressive tumours located within the nervous system), where scientists performed an intratumoral (within the tumour itself) or intraventricular (in the brain fluid) delivery. Patients across the study had a median overall survival of 7.7 months, compared with 10.2 months in the group receiving the upgraded delivery approach.</p><p><strong>My hypothesis for the future of CAR-T therapy:</strong></p><p>Finding a definitive cure for cancer — with its sheer unpredictability, ability to immune-camouflage, and highly heterogenous surface markers — has perplexed researchers for decades and victims when it began its first attack a millennia ago, particularly now as this elusive disease is the second leading cause of death worldwide. This isn’t just about breaking biomedical boundaries; it’s about reimagining the future for millions of cancer-diagnosed patients. In a world so heavily focused on producing generic answers for similar challenges, it encourages us to think of different solutions for different cancers in different locations.</p><p>Yet, I believe CAR-T therapy will launch us close or even onto that optimal threshold for a definitive cure because it can help solve the root cause of cancer — a disease caused by genetic mutations, cured by genetic mutations.</p><p>Personally, looking at the solutions through an analytical standpoint, I believe that regional and local delivery might potentially be the fastest way to deliver promising results for cancer-diagnosed patients. By reducing half the journey, half that energy consumption that CAR-T cells take and consume respectively, this promising method could ensure more effective attacks against these cancerous cells.</p><p>And with hundreds of biotech firms conducting trials, probably even right now as you read this, trying to showcase the immense potential this treatment has — what says that it can’t be the next big milestone for the biomedical field? It’ll keep accelerating, and dare I say: never stop…</p><p><strong>About Me:</strong></p><p>Hi! I am Soumya, a Year 9 student in Dubai and a member of The Knowledge Society (TKS). I’m deeply interested in how biology and technology can help solve our world’s most pressing isues. I thoroughly enjoy exploring emerging ideas, understanding the science behind them and in the wider scope, seeing how this can impact our world today.</p><p><strong>Sources</strong></p><p>1. Children’s Hospital of Philadelphia. Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure at 10 Years. <a href="https://www.chop.edu/news/emily-whitehead-first-pediatric-patient-receive-car-t-cell-therapy-celebrates-cure-10-years">https://www.chop.edu/news/emily-whitehead-first-pediatric-patient-receive-car-t-cell-therapy-celebrates-cure-10-years</a></p><p>2. Penn Medicine. Penn Medicine at the AACR Annual Meeting 2026. <a href="https://pennmedicine.org/news/penn-medicine-at-the-aacr-annual-meeting-2026">https://pennmedicine.org/news/penn-medicine-at-the-aacr-annual-meeting-2026</a></p><p>3. Zhang K et al. (2023). Bright future or blind alley? CAR-T cell therapy for solid tumors. Frontiers in Immunology. <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1045024/full">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1045024/full</a></p><p>4. Journal of Hematology &amp; Oncology (2025). CAR-T therapy for solid tumors: highlights from ASCO 2025. <a href="https://link.springer.com/doi/10.1186/s13045-025-01760-9">https://link.springer.com/doi/10.1186/s13045-025-01760-9</a></p><p>5. OncLive. China’s NMPA Approves First CAR T-Cell Therapy for CLDN18.2+, HER2– Advanced Gastric/GEJ Adenocarcinoma (June 22, 2026). <a href="https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma">https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma</a></p><p>6. CARsgen Therapeutics. CARsgen Announces Approval of Satri-cel (June 22, 2026). <a href="https://www.carsgen.com/en/news/20260622/">https://www.carsgen.com/en/news/20260622/</a></p><p>7. Qi C et al. (2025). Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice (CT041-ST-01). The Lancet. <a href="https://www.themednet.org/publications/claudin-18-isoform-2-specific-car-t-cell-therapy-satri-cel-versus-treatment-of-physicians-choice-for-previously-treated-advanced-gastric-or-gastro-oesophageal-junction-cancer-ct041-st-01-a-randomised-open-label-phase-2-trial">https://www.themednet.org/publications/claudin-18-isoform-2-specific-car-t-cell-therapy-satri-cel-versus-treatment-of-physicians-choice-for-previously-treated-advanced-gastric-or-gastro-oesophageal-junction-cancer-ct041-st-01-a-randomised-open-label-phase-2-trial</a></p><p>8. ScienceAlert. Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial. <a href="https://www.sciencealert.com/?p=163433">https://www.sciencealert.com/?p=163433</a></p><p>9. BioInformant. CAR-T Market Leaders in 2026. <a href="https://bioinformant.com/car-t-market-leaders/amp/">https://bioinformant.com/car-t-market-leaders/amp/</a></p><p>10. ClinicalTrials.gov. EVEREST-2: Mesothelin-Targeting Logic-gated CAR T (A2B694), A2 Biotherapeutics (NCT06051695). <a href="https://clinicaltrials.gov/study/NCT06051695">https://clinicaltrials.gov/study/NCT06051695</a></p><p>11. Penn Medicine. Dual-Target CAR T Cell Therapy Slows Growth of Aggressive Brain Cancer (ASCO 2025). <a href="https://www.pennmedicine.org/news/dual-target-car-t-cell-therapy-slows-growth-of-aggressive-brain-cancer">https://www.pennmedicine.org/news/dual-target-car-t-cell-therapy-slows-growth-of-aggressive-brain-cancer</a></p><p>12. Brown CE et al. (2024). Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nature Medicine. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11031404/">https://pmc.ncbi.nlm.nih.gov/articles/PMC11031404/</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=56b37e898447" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>